ATHE - Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study | Benzinga
- New bioMUSE Data Informs ATH434-202 Study Endpoints -
- Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University -
MELBOURNE, Australia and SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast today on Thursday, 30 May 2024 in Australia / Wednesday, 29 May 2024 in the United States. Details are listed below and registration is required.
The call will feature Alterity's CEO Dr. David Stamler who will discuss the bioMUSE Natural History Study results and their impact on the endpoints for the ATH434-202 Phase 2 clinical trial. Joining the call will be key opinion leader Daniel Claassen, M.D., M.S., Professor of Neurology, Vanderbilt University Medical Center. Dr. Claassen is the Principal Investigator of bioMUSE and the Coordinating Investigator of the ATH434-201 Phase 2 clinical trial.
Webcast details
| AUSTRALIA PARTICIPANTS: |